WO2001062264A3 - Procede d'halotherapie - Google Patents

Procede d'halotherapie Download PDF

Info

Publication number
WO2001062264A3
WO2001062264A3 PCT/US2001/005591 US0105591W WO0162264A3 WO 2001062264 A3 WO2001062264 A3 WO 2001062264A3 US 0105591 W US0105591 W US 0105591W WO 0162264 A3 WO0162264 A3 WO 0162264A3
Authority
WO
WIPO (PCT)
Prior art keywords
sodium chloride
inhalation
doses
periods
administered via
Prior art date
Application number
PCT/US2001/005591
Other languages
English (en)
Other versions
WO2001062264A2 (fr
Inventor
Piotr Zawadzki
Valentin Antonovich Vinogradov
Original Assignee
Procter & Gamble
Piotr Zawadzki
Valentin Antonovich Vinogradov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2000104735/14A external-priority patent/RU2000104735A/ru
Application filed by Procter & Gamble, Piotr Zawadzki, Valentin Antonovich Vinogradov filed Critical Procter & Gamble
Priority to AU2001241636A priority Critical patent/AU2001241636A1/en
Publication of WO2001062264A2 publication Critical patent/WO2001062264A2/fr
Publication of WO2001062264A3 publication Critical patent/WO2001062264A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé efficace de soulagement de la gravité de malaises respiratoires ou de diminution de la durée de ces malaises, en particulier le rhume classique ou la grippe. Ce procédé consiste à administrer à un individu, pendant une période de 1 à 14 jours, par inhalation au moyen d'un distributeur portable, une ou plusieurs doses de chlorure de sodium sous forme d'un aérosol composé de particules de 1 à 5 microns, chaque dose étant constituée par 50 à 5000 microgrammes de chlorure de sodium, administrées par 2 à 200 inspirations. Les distributeurs appropriés consistent en des distributeurs de poudre sèche et en nébuliseurs de liquide. On administre, de préférence, ces doses par rythme comprenant deux ou plusieurs périodes d'inhalation de chlorure de sodium séparées par des périodes de respiration normale. L'invention concerne, de plus, l'utilisation de chlorure de sodium afin préparer un médicament pouvant être administré au moyen de ces procédés.
PCT/US2001/005591 2000-02-23 2001-02-22 Procede d'halotherapie WO2001062264A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001241636A AU2001241636A1 (en) 2000-02-23 2001-02-22 Halotherapy method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2000104735/14A RU2000104735A (ru) 2000-02-23 Способ галотерапии
RU2000104735 2000-02-23

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10257126 A-371-Of-International 2001-02-23
US10/267,708 Continuation-In-Part US6919205B2 (en) 2000-02-23 2002-10-09 Regulation of type II collagen gene expression using specific and selective electrical and electromagnetic signals
US10/603,226 Continuation-In-Part US7130692B2 (en) 2000-02-23 2003-06-25 Portable electrotherapy device for treating osteoarthritis and other diseases, defects and injuries of the knee joint

Publications (2)

Publication Number Publication Date
WO2001062264A2 WO2001062264A2 (fr) 2001-08-30
WO2001062264A3 true WO2001062264A3 (fr) 2002-05-02

Family

ID=20231147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005591 WO2001062264A2 (fr) 2000-02-23 2001-02-22 Procede d'halotherapie

Country Status (2)

Country Link
AU (1) AU2001241636A1 (fr)
WO (1) WO2001062264A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EE00431U1 (et) * 2003-12-09 2004-04-15 Budarin Vladimir Meetod etteantud kontsentratsiooniga soolaaerosooli saamiseks
RO122397B1 (ro) * 2006-11-14 2009-05-29 Constantin Pascu Procedeu şi dispozitiv pentru obţinerea controlată a aerosolilor salini uscaţi
EP2408425A1 (fr) * 2009-03-20 2012-01-25 Livia Tiba Procédé de création d'un aérosol de sel destiné à être respiré par nébulisation d'une solution saline aqueuse
DE102016218604A1 (de) 2016-09-27 2018-03-29 Constantin Adams Partikuläres Stoffgemisch, vorzugsweise zur Verwendung bei der Prophylaxe und/oder Behandlung einer Atemwegsstörung

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028944A1 (fr) * 1994-04-22 1995-11-02 National Heart & Lung Institute Compositions pharmaceutiques contenant un principe actif solide, destinees a l'inhalation
US5487378A (en) * 1990-12-17 1996-01-30 Minnesota Mining And Manufacturing Company Inhaler
WO1996031221A1 (fr) * 1995-04-05 1996-10-10 Genentech, Inc. Preparation de formulations de chlorure de sodium pour aerosol
US5817028A (en) * 1994-02-25 1998-10-06 Central Sydney Area Health Service Method and device for the provocation of air passage narrowing and/or the induction of sputum
WO1998048875A1 (fr) * 1997-04-29 1998-11-05 The Procter & Gamble Company Procede applicable a l'administration de traitement halotherapeutique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487378A (en) * 1990-12-17 1996-01-30 Minnesota Mining And Manufacturing Company Inhaler
US5817028A (en) * 1994-02-25 1998-10-06 Central Sydney Area Health Service Method and device for the provocation of air passage narrowing and/or the induction of sputum
WO1995028944A1 (fr) * 1994-04-22 1995-11-02 National Heart & Lung Institute Compositions pharmaceutiques contenant un principe actif solide, destinees a l'inhalation
WO1996031221A1 (fr) * 1995-04-05 1996-10-10 Genentech, Inc. Preparation de formulations de chlorure de sodium pour aerosol
WO1998048875A1 (fr) * 1997-04-29 1998-11-05 The Procter & Gamble Company Procede applicable a l'administration de traitement halotherapeutique

Also Published As

Publication number Publication date
AU2001241636A1 (en) 2001-09-03
WO2001062264A2 (fr) 2001-08-30

Similar Documents

Publication Publication Date Title
JP5599961B2 (ja) 薬学的組成物
WO2001064182A3 (fr) Ameliorations apportees a l'administration de medicaments par voie orale
US20210330635A1 (en) Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
MY129384A (en) "pharmaceutical formulations for dry powder inhalers in the form of hard-pellets"
WO2003032928A3 (fr) Composition therapeutique et son utilisation
KR20010020346A (ko) 염분치료를 행하는 방법 및 약품의 제조 공정
CA2519175A1 (fr) Procede de traitement d'une maladie systemique
AU2023202420A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
US20230158259A1 (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
WO2001062264A3 (fr) Procede d'halotherapie
Kunkel et al. Respimat®(a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients
SE0303091D0 (sv) Combined doses of tiotropium andfluticasone
O Callaghan et al. The history of inhaled drug therapy
JP2006508994A5 (fr)
CZ287114B6 (en) Therapeutic preparation in the form of aerosol and use of gas mixture
PAVIA et al. Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler
US20170224936A1 (en) Nasal treatment delivery device with carbon dioxide and saline, and methods
RU2362559C2 (ru) Система доставки опиоидов
JP2006508993A5 (fr)
CN116196298A (zh) 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
US20210353536A1 (en) Applying Fluoride for Treating or Preventing Viral Infection Including SARS-CoV-2
EP3411094A1 (fr) Dispositif d'administration de traitement nasal comprenant du dioxyde de carbone et une solution saline, et méthodes, comprenant de faibles débits
RU2000104735A (ru) Способ галотерапии
D’Amato et al. Double-Blind Crossover Study on the Protective Effect of Fenoterol–Administered by Pressurized Aerosol and in Powder Form–in Allergen-Induced Asthma
JP2002161030A (ja) 異なる粒径をもった混合粉体の吸入方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10257126

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP